Protein solution formulation containing high concentration of an anti-VEGF antibody

The present disclosure provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the disclosure comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the disclosure includes a sugar, a buffering agent, and a surfactant.